Evidence map›Paper›PMID 32511367›Full record

ArticlebioRxiv : the preprint server for biology2020

A modular framework for multiscale, multicellular, spatiotemporal modeling of acute primary viral infection and immune response in epithelial tissues and its application to drug therapy timing and effectiveness: A multiscale model of viral infection in epithelial tissues.

T J Sego, Josua O Aponte-Serrano, Juliano Ferrari Gianlupi, Samuel R Heaps, Kira Breithaupt, Lutz Brusch, Jessica Crawshaw, James M Osborne, Ellen M Quardokus, Richard K Plemper and 1 more

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 16 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

T J SegoDepartment of Intelligent Systems Engineering, Indiana University, Bloomington, IN, USA.
Josua O Aponte-SerranoDepartment of Intelligent Systems Engineering, Indiana University, Bloomington, IN, USA.
Juliano Ferrari GianlupiDepartment of Intelligent Systems Engineering, Indiana University, Bloomington, IN, USA.
Samuel R HeapsDepartment of Intelligent Systems Engineering, Indiana University, Bloomington, IN, USA.
Kira BreithauptDepartment of Intelligent Systems Engineering, Indiana University, Bloomington, IN, USA.
Lutz BruschCenter for Information Services and High Performance Computing (ZIH), Technische Universität Dresden, Germany.
Jessica CrawshawSchool of Mathematics and Statistics, University of Melbourne, Melbourne, 3010, Australia.
James M OsborneSchool of Mathematics and Statistics, University of Melbourne, Melbourne, 3010, Australia.
Ellen M QuardokusDepartment of Intelligent Systems Engineering, Indiana University, Bloomington, IN, USA.
Richard K PlemperInstitute for Biomedical Sciences, Georgia State University, Atlanta, GA, USA.
James A GlazierDepartment of Intelligent Systems Engineering, Indiana University, Bloomington, IN, USA.
Indiana University Bloomington · USThe University of Melbourne · AUGeorgia State University · USTechnische Universität Dresden · DE

Funding

Identification and Pre-Clinical Evaluation of Measles Virus InhibitorsR01AI071002 · NIAID · GEORGIA STATE UNIVERSITY · PI PLEMPER, RICHARD K. · 2006 to 2022
$6.6M
Development of a Broad-Spectrum Inhibitor against Seasonal and Highly-Pathogenic Influenza VirusesR01AI141222 · NIAID · GEORGIA STATE UNIVERSITY · PI PLEMPER, RICHARD K. · 2019 to 2023
$5.0M
Novel Therapeutics against Respiratory Syncytial Virus InfectionR01HD079327 · NICHD · GEORGIA STATE UNIVERSITY · PI PLEMPER, RICHARD K. · 2014 to 2018
$2.8M
Competitive Renewal of Development, Improvement and Extension of the Tissue Simulation Environment - CompuCell3DR01GM122424 · NIGMS · TRUSTEES OF INDIANA UNIVERSITY · PI GLAZIER, JAMES ALEXANDER · 2017 to 2020
$1.7M
Dissemination of libRoadRunner and CompuCell3DU24EB028887 · NIBIB · UNIVERSITY OF WASHINGTON · PI GLAZIER, JAMES ALEXANDER, SAURO, HERBERT M. · 2019 to 2023
$1.5M
NIAID NIH HHS R01 AI071002NIAID NIH HHS R01 AI141222NIBIB NIH HHS U24 EB028887NICHD NIH HHS R01 HD079327NIGMS NIH HHS R01 GM122424
6 · The paper itself

Abstract

Simulations of tissue-specific effects of primary acute viral infections like COVID-19 are essential for understanding disease outcomes and optimizing therapies. Such simulations need to support continuous updating in response to rapid advances in understanding of infection mechanisms, and parallel development of components by multiple groups. We present an open-source platform for multiscale spatiotemporal simulation of an epithelial tissue, viral infection, cellular immune response and tissue damage, specifically designed to be modular and extensible to support continuous updating and parallel development. The base simulation of a simplified patch of epithelial tissue and immune response exhibits distinct patterns of infection dynamics from widespread infection, to recurrence, to clearance. Slower viral internalization and faster immune-cell recruitment slow infection and promote containment. Because antiviral drugs can have side effects and show reduced clinical effectiveness when given later during infection, we studied the effects on progression of treatment potency and time-of-first treatment after infection. In simulations, even a low potency therapy with a drug which reduces the replication rate of viral RNA greatly decreases the total tissue damage and virus burden when given near the beginning of infection. Many combinations of dosage and treatment time lead to stochastic outcomes, with some simulation replicas showing clearance or control (treatment success), while others show rapid infection of all epithelial cells (treatment failure). Thus, while a high potency therapy usually is less effective when given later, treatments at late times are occasionally effective. We illustrate how to extend the platform to model specific virus types (

Identifiers

PMID32511367
PMCPMC7263495
OpenAlexW3023638745

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.